| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -5,797,365 | -3,821,353 |
| Stock-based compensation expense | 737,844 | 565,492 |
| Amortization of held-to-maturity securities, net | -20,750 | -15,996 |
| Gain from the sale of investment in alphazyme | - | 0 |
| Amortization of debt issuance costs | 36,104 | 23,794 |
| Foreign currency exchange loss (gain), net | -35,924 | -23,170 |
| Interest receivable | 9,869 | 10,488 |
| Accounts receivable | 673,302 | 471,860 |
| Prepaid expenses and other current assets | 36,916 | -218,050 |
| Operating lease assets and liabilities | -133 | 11 |
| Accounts payable | 681,546 | 224,080 |
| Accrued expenses | 633,522 | 191,009 |
| Accrued interest | -20,000 | 0 |
| Accrued interest - related party | -2,040 | -5,373 |
| Deferred research and development obligations | 503,325 | 999,718 |
| Net cash (used in) operating activities | -3,932,110 | -2,079,746 |
| Proceeds from the sale of investment in alphazyme | - | 0 |
| Purchases of held-to-maturity investment securities | 5,090,846 | 4,560,278 |
| Proceeds from maturities of investment securities | 4,704,772 | 4,080,762 |
| Net cash (used in) investing activities | -386,074 | -479,516 |
| Proceeds from public offering, net of offering costs of 808,760 | 4,940,696 | - |
| Proceeds from exercise of stock | 24,249 | 24,249 |
| Proceeds from issuance of convertible notes, net of issuance costs - related party | - | 0 |
| Proceeds from issuance of convertible notes, net of issuance costs | - | 0 |
| Net cash provided by financing activities | 4,964,945 | 24,249 |
| Effect of exchange rate changes on cash | 2,277 | 2,693 |
| Net decrease in cash, cash equivalents and restricted cash and cash equivalents | 649,038 | -2,532,320 |
| Cash and cash equivalents at beginning of period | 6,506,750 | - |
| Cash and cash equivalents at end of period | 7,155,788 | - |
DYADIC INTERNATIONAL INC (DYAI)
DYADIC INTERNATIONAL INC (DYAI)